Provider Review6 min read

Sunlight GLP-1 Review: $159/Month Semaglutide for Men

A new June 2026 entrant offering compounded semaglutide at $159/month and tirzepatide at $239/month. Here's everything men need to know.

June 19, 2026

Sunlight Quick Facts

Sunlight is a new telehealth GLP-1 provider that launched in June 2026 with pricing that sits in the competitive middle ground — more affordable than many established platforms but not the absolute cheapest. The question for men: is it the right balance of price, service, and reliability?

Pricing Breakdown

MedicationFirst MonthOngoing
Compounded semaglutide$159$179/mo
Compounded tirzepatide$239$259/mo

The introductory pricing is a common telehealth strategy — a lower first-month rate to reduce the barrier to trying the medication, with the ongoing rate kicking in from month two. At $179/mo ongoing for semaglutide, Sunlight sits between GobyMeds ($99/mo) and mid-tier providers like Eden ($239/mo).

How Sunlight Compares

ProviderSemaglutideTirzepatideExtras
GobyMeds$99/mo$133/moNAD+, Sermorelin
Sunlight$159/$179$239/$259
Care Barefrom $199/moAvailable
Eden Healthfrom $239/moAvailable
Yucca Healthfrom $146/mofrom $258/mo6-month bundles
Sesame Carefrom $175/moAvailableBrand-name only

What Stands Out

Mid-Range Value

Sunlight occupies a sensible position for men who want affordable compounded GLP-1 access without going with the absolute cheapest option. If you're willing to pay $60–80 more per month than GobyMeds, you may get more established pharmacy sourcing and customer support infrastructure as the platform matures.

Straightforward Model

No bundle commitments, no platform fees, no complicated pricing tiers. The listed price is what you pay, consultation included. For men who've been frustrated by surprise fees from other platforms, this simplicity is refreshing.

What to Watch

New Platform

Launching in June 2026 means Sunlight doesn't have a long track record yet. Early adoption carries inherent uncertainty about long-term support quality, pharmacy sourcing consistency, and platform stability. This isn't necessarily a dealbreaker — every provider started somewhere — but it's worth noting for men who prioritize established track records.

Regulatory Timing

Sunlight is entering the compounded GLP-1 market at a time when the FDA has proposed excluding semaglutide and tirzepatide from the 503B bulks list, with a June 29, 2026 comment deadline. All compounded GLP-1 providers face regulatory uncertainty. Sunlight's sustainability depends on the same regulatory outcomes as every other compounding-based platform.

Who Should Consider Sunlight

Sunlight makes the most sense for men who want compounded GLP-1 access at a mid-range price point, prefer simple all-in pricing without bundles or commitments, and are comfortable being an early adopter of a new platform. If absolute lowest price is your priority, GobyMeds is cheaper. If you want brand-name medications, Sesame Care is the better fit.

EDITOR'S PICK

Sunlight

Compounded • GLP-1
$159/mo sema · $239/mo tirz

Semaglutide $159 first month/$179 ongoing. Tirzepatide $239/$259. New for June 2026.

View Sunlight →
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies based on a provider's prescription.

Alternatives

GobyMeds

Direct Affiliate • GLP-1 + Peptides
$99/mo semaglutide · $133/mo tirzepatide

If price is the primary factor. Semaglutide $99/mo, tirzepatide $133/mo.

Save $25 off →
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies based on a provider's prescription.

Sesame

Brand-Name • GLP-1
from $175/mo

If you prefer brand-name Ozempic, Wegovy, Mounjaro, or Zepbound. From $175/mo.

Start Your Consultation
Sesame Care provides access to brand-name GLP-1 medications only (Ozempic, Wegovy, Mounjaro, Zepbound).

The Bottom Line

Sunlight is a solid new entrant in the compounded GLP-1 market for men, offering competitive mid-range pricing ($159–$179/mo semaglutide, $239–$259/mo tirzepatide) with simple all-in pricing. It's a reasonable choice for men who want something between the cheapest options and the premium platforms. The main caveat is the new-platform risk common to any June 2026 launch, compounded by industry-wide regulatory uncertainty.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. Individual results vary. GLP-1 medications carry risks including gastrointestinal side effects and, rarely, pancreatitis or thyroid concerns. Discuss your full medical history with your provider.